Q-omics provides the consensus-scored TLCD4 profile across patient tissues and cancer cell-line models. TLCD4 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, TLCD4 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, TLCD4 RNA expression shows 18,794 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, and THYM as cancer lineages where TLCD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLCD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLCD4 survival associations across molecular data types. TLCD4 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLCD4 RNA expression–survival associations across cancer types. High TLCD4 expression shows favorable associations in COAD, SKCM, KIRC, OV, BRCA and HNSC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for TLCD4 RNA expression.
This table summarizes TLCD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TLCD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLCD4 shows lower tumor expression in COAD, KIRC, LUSC, BLCA, KICH and LUAD. The COAD box plot shows higher TLCD4 RNA expression in normal versus tumor tissue (log2 FC = −2.082, t-test p < 0.001).
This table shows molecular features associated with TLCD4 in patient tissues and cancer cell lines. In patient samples, TLCD4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TLCD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
